Elicio Therapeutics, Inc. (ELTX)
Nasdaq · Healthcare · Biotechnology
$1.920.00%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $50.5M
- 52-week range
- $1.71 – $16.00
- 52-week change
- −82.21%
- EPS (trailing)
- −$2.16
- Analyst rating
- 1.5 Strong buy
Fiscal year to Dec 2025
- Net income
- −$39.6M
- Diluted EPS
- −$2.58
- Free cash flow
- −$37.0M
From the company’s annual report on SEC EDGAR.
About Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Headquarters: Boston, United States · 33 employees · elicio.com